Literature DB >> 17913610

Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels.

I Lenci1, P Piccolo, S Francioso, D Di Paolo, A Galante, M Angelico.   

Abstract

A 63-year-old man with chronic hepatitis C and persistently normal alanine aminotransferase levels was treated with peginterferon alpha-2a (180 microg weekly) and ribavirin (800 mg daily). Hepatitis C virus-ribonucleic acid was negative at week 4. After 12 weeks of therapy, haemoglobin levels had decreased by 3.5mg/dL, and he developed a syncope episode with electrocardiographic signs of myocardial ischaemia. Antiviral treatment was stopped and the ischaemia-like electrocardiographic changes resolved completely within 2 months. Eight months later, because of the previous rapid virological response and patient motivation, he was treated again with peginterferon and ribavirin. Baseline and weekly electrocardiographic recordings were obtained during treatment. At week 4 hepatitis C virus-ribonucleic acid was negative. At week 8, when the haemoglobin levels had decreased by 3.4 mg/dL, the patient developed the same ischaemia-like changes that occurred during the previous treatment. Antiviral therapy was stopped and the electrocardiographic ischaemia-like changes disappeared after 1 month. The patient neither had a history of previous cardiovascular diseases, nor evidence of current disease at myocardial scintigraphy. However, a coronary microvessel spasm, possibly related to drug-toxicity and/or anaemia could not be excluded. This case indicates the need of strict electrocardiographic monitoring in elderly patients undergoing treatment with peginterferon and ribavirin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913610     DOI: 10.1016/j.dld.2007.03.010

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  2 in total

Review 1.  Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms.

Authors:  Joy N Jones Buie; Jim C Oates
Journal:  Am J Med Sci       Date:  2014-08       Impact factor: 2.378

2.  Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.

Authors:  Eric Lawitz; Edward Gane; Eric Cohen; John Vierling; Kosh Agarwal; Tarek Hassanein; Parvez S Mantry; Paul J Pockros; Michael Bennett; Nyingi Kemmer; Giuseppe Morelli; Jiuhong Zha; Deli Wang; Nancy S Shulman; Daniel E Cohen; K Rajender Reddy
Journal:  Kidney Int Rep       Date:  2018-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.